|1.||Drucker, Daniel J: 17 articles (10/2014 - 05/2006)|
|2.||Greig, Nigel H: 12 articles (02/2014 - 03/2002)|
|3.||Knop, Filip K: 9 articles (01/2015 - 08/2009)|
|4.||Wild, Damian: 9 articles (01/2015 - 12/2006)|
|5.||Vilsbøll, Tina: 7 articles (12/2015 - 01/2010)|
|6.||Reubi, Jean Claude: 7 articles (10/2013 - 12/2006)|
|7.||Seino, Yutaka: 6 articles (03/2015 - 02/2008)|
|8.||Mannucci, Edoardo: 6 articles (02/2015 - 06/2009)|
|9.||Holst, Jens J: 6 articles (12/2014 - 07/2008)|
|10.||Li, Yazhou: 6 articles (02/2014 - 01/2009)|
|1.||Type 2 Diabetes Mellitus (MODY)
01/01/2012 - "GLP-1 receptor agonists have been shown to be effective in the treatment of type 2 diabetes mellitus (T2DM). "
03/01/2015 - "To review the pharmacology, pharmacokinetics, safety, and efficacy of the glucagon-like peptide-1 receptor agonist (GLP-1 RA), dulaglutide, in the treatment of type 2 diabetes mellitus (T2D). "
08/01/2014 - "Pharmacokinetics, safety, and efficacy of DPP-4 inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes mellitus and renal or hepatic impairment. "
01/01/2014 - "The aim of this study was to evaluate the dose-dependent effect of dulaglutide, a glucagon-like peptide-1 receptor agonist, on glycaemic control in Japanese patients with type 2 diabetes mellitus who were treated with diet/exercise or oral antidiabetic drug monotherapy. "
07/01/1994 - "To study the relationship between the GLP-1 receptor gene and NIDDM, linkage of a microsatellite polymorphism flanking the GLP-1 receptor gene with diabetes was investigated in three Caucasian families with MODY and in the nuclear families of 12 NIDDM probands. "
|2.||Weight Loss (Weight Reduction)
03/01/2015 - "The GLP-1 receptor agonists have proven efficacy in the treatment of type 2 diabetes and may provide patients with additional nonglycemic benefits, including significant weight loss and decreased systolic blood pressure. "
07/01/2012 - "GLP-1 receptor agonists have been shown to be effective in the treatment of type 2 diabetes, including aiding with A1C reduction and weight loss. "
01/01/2012 - "Clinical trials have also demonstrated statistically significant weight reduction, small beneficial effects on blood pressure, and unchanged lipid profiles with GLP-1 receptor agonists. "
01/01/2012 - "Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials."
09/01/2009 - "A comparison of the study data differentiates the clinical profiles of the GLP-1 receptor agonists, which are associated with weight loss, and DPP-4 inhibitors, which are weight neutral, as well as the individual agents within each class."
04/01/2013 - "These results provide preliminary evidence supporting the feasibility, safety, and efficacy of GLP-1 receptor agonist therapy for the treatment of severe obesity in adolescents. "
01/01/2016 - "Glucagon-Like Peptide-1 Receptor Agonist Treatment for Pediatric Obesity."
07/01/2013 - "Glucagon-like peptide-1 receptor in the brain: role in neuroendocrine control of energy metabolism and treatment target for obesity."
04/01/2013 - "The effect of glucagon-like peptide-1 receptor agonist therapy on body mass index in adolescents with severe obesity: a randomized, placebo-controlled, clinical trial."
07/01/2010 - "Coadministration of Y2 receptor agonists and GLP-1 receptor agonists may be a useful treatment strategy for obesity."
|4.||Body Weight (Weight, Body)
07/01/2015 - "Clinical studies with GLP-1 receptor agonists consistently show that, in addition to good antidiabetic efficacy, its long-term administration decreases blood pressure, body weight and improves circulating lipid levels while slightly increasing heart rate. "
12/01/2014 - "GLP-1 receptor agonists, currently used for the treatment of type 2 diabetes (T2DM), improve glycemic control and stimulate satiety, leading to decreases in food intake and body weight. "
03/01/2014 - "GLP-1 receptor signaling is not required for reduced body weight after RYGB in rodents."
02/01/2014 - "Although Ex (9-39) administration did not significantly affect food consumption, it resulted in a marked body weight gain, indicating that the GLP-1 receptor antagonist caused a positive energy balance. "
02/01/2014 - "Concurrent pharmacological modification of cannabinoid-1 and glucagon-like peptide-1 receptor activity affects feeding behavior and body weight in rats fed a free-choice, high-carbohydrate diet."
|5.||Hypoglycemia (Reactive Hypoglycemia)
02/01/2015 - "Glucagon-like peptide-1 receptor agonists (GLP-1 RA) are attractive options for the treatment of type 2 diabetes (T2D) because they effectively lower A1C and weight while having a low risk of hypoglycemia. "
12/01/2014 - "Furthermore, GLP-1 receptor agonist treatment is associated with a very low hypoglycemia risk. "
11/01/2014 - "The glucagon-like peptide-1 receptor agonists (GLP-1 RAs) offer a treatment option that improves glycemic control and reduces weight, with a low risk of hypoglycemia. "
10/01/2011 - "GLP-1 receptor agonists can fill an unmet therapeutic need in the treatment of T2DM: improving glycemic control without increasing the risk of hypoglycemia (except with concomitant sulfonylureas) and reducing weight in a substantial proportion of patients. "
09/01/2009 - "GLP-1 receptor agonists and DPP-4 inhibitors address different pathophysiologic causes than do other diabetes medications and offer the benefit of a low incidence of hypoglycemia. "
|5.||Glucagon-Like Peptide 1 (GLP 1)
|9.||Blood Glucose (Blood Sugar)